Form 8-K - Current report

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2024

BIOADAPTIVES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

000-54949

46-2592228

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2620 Regatta Drive, Suite 102

Las Vegas, Nevada 89128

(Address of Principal Executive Office) (Zip Code)

(702) 659-8829

Registrant's telephone number, including area code:

N/A

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 20, 2024, the Shareholders of BioAdaptives Inc accepted the resignation of the Chairman of the Board Edward Jacobs for personal reasons and the resignation of Board Member Robert Ellis also for personal reasons. In the same meeting, the Shareholders elected James Keener as Chairman of the Board and currently the sole Member of the Board.

On May 20, 2024, following the shareholders meeting the Board of Directors of BioAdaptives Inc met and accepted the resignation of the CEO Edward Jacobs for personal reasons and the resignation of President Robert Ellis also for personal reasons. The Board of Directors then elected James Keener to the position of CEO and currently the sole Officer.

Item 7.01 Regulation FD Disclosure

The Company issued a press release on May 21, 2024, announcing the departure of Dr .Edward Jacobs, Jr and Mr Robert Ellis and the appointment of Mr. James Keener as the Company’s Director and CEO.

A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description

99.1		Press Release

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

May 22, 2024		BioAdaptives, Inc.

		/s/ James Keener
		James Keener
		Director and CEO

null

Cover	May 20, 2024
Cover [Abstract]
Entity Registrant Name	BIOADAPTIVES, INC.
Entity Central Index Key	0001575142
Document Type	8-K
Amendment Flag	false
Entity Emerging Growth Company	false
Document Period End Date	May 20, 2024
Entity File Number	000-54949
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	46-2592228
Entity Address Address Line 1	2620 Regatta Drive
Entity Address Address Line 2	Suite 102
Entity Address City Or Town	Las Vegas
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89128
City Area Code	702
Local Phone Number	659-8829
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false